OncoMed Pharma (OMED) Tops Q2 EPS by 10c

OncoMed Pharma (NASDAQ: OMED) reported Q2 EPS of ($0.40), $0.10 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $6.2 million versus the consensus estimate of $4.85 million.

For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c